Search
for

    Research

    2 / 1000+ results

      research Tebentafusp-tebn (Kimmtra®)

      March 2022 in “Oncology Times”
      Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
      Ocular Oncology Yesterday And Today

      research ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ

      January 2024 in “Wiadomości Lekarskie”
      Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.